Acumen Pharmaceuticals financials
$2.25−2.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$123.8M | -$114.0M | -$61.1M | -$45.2M | -$19.6M |
| Net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M | -$100.6M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-5.02 |
| EBITDA | -$123.8M | -$114.0M | -$61.1M | -$45.1M | -$19.6M |
| Operating cash flow | -$115.5M | -$86.2M | -$43.1M | -$35.2M | -$18.0M |
| Free cash flow | -$115.6M | -$86.2M | -$43.1M | -$35.3M | -$18.0M |
| Diluted shares | 60.6M | 60.0M | 48.6M | 40.6M | 20.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $54.0M | $35.6M | $66.9M | $130.1M | $122.2M |
| Short-term investments | $62.9M | $135.9M | $176.6M | $47.5M | $72.1M |
| Total debt | $31.2M | $29.4M | $30.7M | $0.00 | $0.00 |
| Total assets | $122.8M | $239.0M | $310.1M | $196.6M | $230.3M |
| Total liabilities | $52.4M | $57.2M | $43.2M | $7.8M | $5.1M |
| Shareholders' equity | $70.4M | $181.8M | $267.0M | $188.8M | $225.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology